Selexys completes SelG1 trial in Sickle Cell disease

SelG1 is an investigational humanized monoclonal antibody directed against P-selectin, a key member of the adhesion molecule family known as the selectins.

The placebo-controlled, double-blind, ascending single dose and multiple dose study of SelG1 enrolled 27 healthy subjects to evaluate the safety and pharmacology of SelG1.

SelG1 appeared to be safe and well tolerated, with no significant adverse events in any subjects and an immune response to SelG1 was not observed during the study.

Analysis of SelG1 pharmacokinetic and pharmacodynamic data demonstrated a serum half-life of approximately two weeks and complete blockade of P-selectin activity in all patients for at least one month following a single intravenous dose.

The company expects the data of the Phase I trial to help in the advancement of the drug compound into a Phase II clinical trial in patients with sickle cell disease.